Targeting Protein Aggregation and Degradation in Age-Related Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 130
Special Issue Editors
Interests: redox biology; aging-related disorders; ferroptosis; thiols; post-translational modifications; proteomics; protein aggregation and degradation; proteasome; persulfidation; hydrogen sulfide; protein structure and function; enzymology; peroxidases; drug discovery; drug repurposing
Interests: bioactive compounds; cell signaling; drug delivery; drug discovery; enzymology; high-throughput screening; metalloproteases; molecular pharmacology; nanoparticles; neuropeptides; neurodegenerative diseases; parkinson's disease; protein-protein interaction inhibitors; protein engineering; protein structure; protease inhibitors; protein folding and aggregation; substrate specificity; X-ray crystallography
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Aging and aging-related diseases are typically characterized by a decline in protein degradation systems, leading to the accumulation of damaged or misfolded proteins. Moreover, oxidative damage is often highlighted as one of the main drivers of aging, resulting in cellular dysfunction and contributing to the development of various disorders, including neurodegenerative, cardiovascular, metabolic, musculoskeletal, and immune system diseases. In this context, the ubiquitin-proteasomal system (UPS) and the autophagy-lysosomal system (ALS) are commonly dysregulated, ultimately leading to the formation of oxidatively damaged and aggregated proteins.
The focus of this Special Issue is on the development and identification of novel pharmacologically active molecules targeting protein aggregation and degradation pathways in the context of aging and age-related diseases. This may include the repurposing of known inhibitors, anti-aggregational, antioxidative, and/or anti-inflammatory molecules, or the development of new ones. We also emphasize novel formulations and nanomaterials targeting protein aggregation and degradation mechanisms.
Dr. Martín Hugo
Dr. Javier Garcia-Pardo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- aging
- aggregation inhibitor
- alzheimer disease
- amyloidoses
- antioxidant compounds
- anti-inflammatory
- autophagy
- α-synucleinopathies
- cell signaling
- cysteine
- drug delivery
- drug discovery
- high-throughput screening
- nanotechnology
- neurodegenerative diseases
- oxidation
- parkinson’s disease
- phase separation
- protease inhibitor
- proteasome
- proteostasis
- protein aggregation
- redox
- stress granule
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
